{"tid":2364626,"cid":5,"subCid":0,"title":"無懼中國疫苗有效率僅50% 印尼總統全國直播注射過程","createTime":"2021-01-13T06:38:17.000Z","updateTime":"2021-01-13T07:08:00.000Z","uid":337052,"like":2,"dislike":2,"uniUserReply":6,"replies":[{"pid":"6db3f02e41c2ccdd8946a69ebf8935cc8dd993c5","tid":2364626,"uid":337052,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-13T06:38:17.000Z","msg":"印尼總統佐科維多多接種首劑科興疫苗<br />\n<br />\n<img src=\"https://cdn.hk01.com/di/media/images/dw/20210113/425996626092363776014832.jpeg/Cf9bjiGOZVN8NgKY1eFx6dHY_P-aTlg7dYVaI3WFWiM?v=w1920\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Fcdn.hk01.com%2Fdi%2Fmedia%2Fimages%2Fdw%2F20210113%2F425996626092363776014832.jpeg%2FCf9bjiGOZVN8NgKY1eFx6dHY_P-aTlg7dYVaI3WFWiM%3Fv%3Dw1920&h=e9cbc3b4&s={SIZE}\" /><br />\n<br />\n即時國際<br />\n<br />\n撰文：王慧珊<br />\n2021-01-13 12:07<br />\n最後更新日期：2021-01-13 12:10<br />\n<br />\n<span class=\"red\">印尼總統佐科維多多（Joko Widodo ）1月13日早上接種中國科興生物（Sinovac Biotech）研製的新型冠狀病毒肺炎（COVID-19）疫苗，成為當地第一人接種新冠疫苗。</span><br />\n<br />\n<img src=\"https://cdn.hk01.com/di/media/images/dw/20201119/406163978012594176834061.jpeg/t7OevHSJLU68XdeGBHyvTWltUBAhKYY9wDOxV8AzsVc?v=w1920\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Fcdn.hk01.com%2Fdi%2Fmedia%2Fimages%2Fdw%2F20201119%2F406163978012594176834061.jpeg%2Ft7OevHSJLU68XdeGBHyvTWltUBAhKYY9wDOxV8AzsVc%3Fv%3Dw1920&h=448e9f07&s={SIZE}\" /><br />\n圖為2020庠11月19日，印尼總統佐科維多多在亞太經合組織工商領導人對話會上發言。（AP）<br />\n<br />\n佐科維多多13日早上在總統府接種科興疫苗，<span class=\"red\">整個注射過程透過當地電視台直播。 </span>隨着佐科維多多接種第一針疫苗，印尼全國開始推行接種計劃。<br />\n<br />\n從本周開始，估計印尼將有148萬名衛生工作者會接種疫苗。預料1月份將有逾56萬人接種，其餘90萬人會在2月份接種。"},{"pid":"e688f6cbd82fc8e6ec98a63bb598f582d625615e","tid":2364626,"uid":66365,"like":2,"dislike":1,"score":1,"citedBy":0,"replyTime":"2021-01-13T06:41:00.000Z","msg":"窮撚國家就係咁<img src=\"/assets/faces/normal/sosad.gif\" class=\"hkgmoji\" />"},{"pid":"b0f1ac535b836d05f907d8783db55f75d8bda101","tid":2364626,"uid":337052,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-13T06:41:20.000Z","msg":"<strong><span class=\"x-large\">央視大加表揚</span></strong><br />\n<br />\n印尼總統佐科接種中國新冠疫苗<br />\n來源：<span class=\"red\">央視新聞</span>客戶端<br />\n<br />\n2021-01-13 11:16<br />\n<br />\n<a href=\"http://1400174353.vod2.myqcloud.com/d1db0086vodtranscq1400174353/c0c84cc15285890812652000654/v.f30.mp4\" data-sr-url=\"https://r.lihkg.com/link?u=http%3A%2F%2F1400174353.vod2.myqcloud.com%2Fd1db0086vodtranscq1400174353%2Fc0c84cc15285890812652000654%2Fv.f30.mp4&d=Eu1QSTPz0OFPBNy7%2BevvEfpmn865KX7g3oX29oYbiiE%3D&h=9a17e840\" data-auto-link target=\"_blank\">http://1400174353.vod2.myqcloud.com/d1db0086vodtranscq1400174353/c0c84cc15285890812652000654/v.f30.mp4</a><br />\n視頻製作：胡適真<br />\n<br />\n當地時間13日上午9時50分，<span class=\"red\">印尼總統佐科按期在總統府打了第一針新冠疫苗，這針疫苗是來自中國科興生物製藥公司的產品。</span><br />\n<br />\n<img src=\"https://rs1.huanqiucdn.cn/dp/api/files/imageDir/a44c7433a557de9a92c1a314990f9487.jpg\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Frs1.huanqiucdn.cn%2Fdp%2Fapi%2Ffiles%2FimageDir%2Fa44c7433a557de9a92c1a314990f9487.jpg&h=54fe9a70&s={SIZE}\" /><br />\n<br />\n來自宗教界、商務界、健康部門的代表在現場共同見證了這一歷史時刻。這次注射還在網絡平台上進行了直播，很多印尼民眾在網上觀看了直播視頻。 （總台記者 賈建京）"},{"pid":"9f173f7fdb22c5fdab49f098a7e6598b41995d22","tid":2364626,"uid":117837,"like":0,"dislike":0,"score":0,"citedBy":1,"replyTime":"2021-01-13T06:42:23.000Z","msg":"人哋打第二隻你知閪咩"},{"pid":"d4a7589cf28cee6099a6a8d297da3bde6025c112","tid":2364626,"uid":337052,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-13T06:46:07.000Z","msg":"<strong><span class=\"x-large\">巴西調降中國疫苗保護力至50.4％ 中官媒急「護航」</span></strong><br />\n2021/01/13 14:25<br />\n<br />\n〔財經頻道／綜合報導〕曾號稱武漢肺炎（新型冠狀病毒病，COVID-19）疫苗效用率高達90%的中國藥廠「科興生物」，<span class=\"red\">昨（12日）慘遭巴西布坦坦研究所（Instituto Butantan）公布的臨床實驗數據打臉，顯示該疫苗整體有效率只有50.4%，勉強通過巴西的疫苗上市規定50%門檻。</span>對此，<span class=\"red\">中國官媒「環球時報」做出回應，指巴西參與試驗的對象皆為高風險族群，該疫苗對普通民眾會有更好保護力。</span><br />\n<br />\n綜合外電報導，巴西搶先對1.3萬人測試中國科興疫苗，原本3期臨床實驗數據應在12月初公布，延到12月22日未公布，再推延15天，於本月7日公布「重症患者」測試結果，稱科興疫苗的有效率為78％，受到學者質疑。昨日，布坦坦研究所再次公布最新臨床實驗數據，此次加入輕中症病患測驗結果，使科興疫苗整體有效率降至50.4%，遠低於7日宣布的78%有效率，令巴西當局大失所望。<br />\n<br />\n對於布坦坦研究所公布的最新臨床實驗數據結果，《環球時報》今（13日）也做出回應，並引述中國疾控中心專家說法，<span class=\"red\">指實驗數據結果顯示科興生物疫苗對中重症有較高的保護效力，並指由於參與巴西3期臨床試驗的對象都是高風險的醫務人員，認為所得的試驗數據結果「已夠好了」，稱該疫苗若對普通民眾會有更好保護力。</span><br />\n<br />\n由於臨床實驗數據一再延遲公布與疫苗在測試過程中曾傳出有接種人死亡等問題，也開始讓巴西當局猶豫是否准科興疫苗上市，據悉巴西衛生監督局預計將在本月17日開會，就批准科興疫苗緊急使用許可一事，進行討論。<br />\n<br />\n<a href=\"https://ec.ltn.com.tw/article/breakingnews/3409628\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fec.ltn.com.tw%2Farticle%2Fbreakingnews%2F3409628&d=Eu1QSTPz0OFPBNy7%2BevvEfpmn865KX7g3oX29oYbiiE%3D&h=444644e4\" data-ef-url=\"https://embed.lih.kg/frame?u=https%3A%2F%2Fec.ltn.com.tw%2Farticle%2Fbreakingnews%2F3409628&h=1ff9ea2f\" data-auto-link target=\"_blank\">https://ec.ltn.com.tw/article/breakingnews/3409628</a>"},{"pid":"8c313c2e693f1383e258c13ec735016ad9731e6a","tid":2364626,"uid":237143,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-13T06:49:01.000Z","msg":"一係中 一係唔中<img src=\"/assets/faces/dog/hehe.gif\" class=\"hkgmoji\" />"},{"pid":"df979817a811ec5714869dae80bf620eed9c07be","tid":2364626,"uid":337052,"like":2,"dislike":0,"score":2,"quote":{"pid":"9f173f7fdb22c5fdab49f098a7e6598b41995d22","tid":2364626,"uid":117837,"like":0,"dislike":0,"score":0,"citedBy":1,"replyTime":"2021-01-13T06:42:23.000Z","msg":"人哋打第二隻你知閪咩"},"citedBy":0,"replyTime":"2021-01-13T06:59:39.000Z","msg":"印尼總統佐科維多多接種首劑科興疫苗"},{"pid":"f793ebd3421d6990a8fe0e7573ccd15c2e4b608c","tid":2364626,"uid":155095,"like":1,"dislike":0,"score":1,"citedBy":0,"replyTime":"2021-01-13T07:00:37.000Z","msg":"習近平：多謝白老鼠幫我做試驗 <img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" />"},{"pid":"321499ef597f56842dc6932228e642e9b7c63b0a","tid":2364626,"uid":140283,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-13T07:08:00.000Z","msg":"咁樣先好 遲啲中咗就親身力證無效 說服力大增<img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" />"}]}